159191-44-3

Usage

Uses

Used in Organic Synthesis:
4-(Dibenzylamino)phenylboronic acid is utilized as a reagent in organic synthesis, specifically for the formation of carbon-carbon bonds through the Suzuki coupling reaction. This reaction is a powerful method for creating new chemical entities, making 4-(DIBENZYLAMINO)PHENYLBORONIC ACID a valuable tool in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-(Dibenzylamino)phenylboronic acid serves as a building block for the synthesis of biologically active molecules and pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Materials Science:
4-(Dibenzylamino)phenylboronic acid has been investigated for its potential application in materials science, particularly in the development of organic electronic materials and sensors. Its properties make it a candidate for use in creating advanced materials with specific electronic or sensing capabilities.
Used in Pharmaceutical Development:
4-(Dibenzylamino)phenylboronic acid is used as a key intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs with improved efficacy and selectivity.
Safety Considerations:
It is important to handle 4-(Dibenzylamino)phenylboronic acid with caution due to its potential reactivity and toxicity. Proper safety measures should be taken during its synthesis, storage, and use to minimize risks to health and the environment.

InChI:InChI=1/C20H20BNO2/c23-21(24)19-11-13-20(14-12-19)22(15-17-7-3-1-4-8-17)16-18-9-5-2-6-10-18/h1-14,23-24H,15-16H2

Upstream product

• 106-40-1 4-bromo-aniline 
• 65145-14-4 N,N-dibenzyl-4-bromoaniline 
• 5419-55-6 Triisopropyl borate 

Downstream Products

• 1225380-08-4 ethyl {3-[4-(dibenzylamino)phenyl]oxetan-3-yl}acetate 
• 1225380-09-5 2-{3-[4-(dibenzylamino)phenyl]oxetan-3-yl}ethanol 
• 1227160-10-2 2-{1-[4-(dibenzylamino)phenyl]cyclobutyl}-N,N-dimethylacetamide 
• 1227160-09-9 {1-[4-(dibenzylamino)phenyl]cyclobutyl}acetic acid 
• 1227159-96-7 N,N-dibenzyl-4-[1-(2-fluoroethyl)cyclobutyl]aniline 
• 1227159-95-6 2-{1-[4-(dibenzylamino)phenyl]cyclobutyl}ethanol 
• 1227159-94-5 ethyl {1-[4-(dibenzylamino)phenyl]cyclobutyl}acetate 
• 1225380-13-1 4-(3-methyloxetan-3-yl)benzenecarbonitrile 
• 1225380-12-0 4-(3-methyloxetan-3-yl)aniline 
• 1225380-11-9 N,N-dibenzyl-4-(3-methyloxetan-3-yl)aniline 
• 1225380-10-8 {3-[4-(dibenzylamino)phenyl]oxetan-3-yl}acetaldehyde 

Relevant academic research and scientific papers

Ligand Aspect Ratio as a Decisive Factor for the Self-Assembly of Coordination Cages

It is possible to control the geometry and the composition of metallasupramolecular assemblies via the aspect ratio of their ligands. This point is demonstrated for a series of iron- and palladium-based coordination cages. Functionalized clathrochelate co

HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS

The present application relates to novel aryl compounds with heterocyclic substituents, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention

HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS

The present application relates to novel substituted aryl compounds, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

Aryl compounds with aminoalkyl substituents and their use

The present application relates to novel aryl compounds with aminoalkyl substituents, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.